[go: up one dir, main page]

CA2361636A1 - Utilisation d'amides d'acides pyrazol-carboxyliques - Google Patents

Utilisation d'amides d'acides pyrazol-carboxyliques Download PDF

Info

Publication number
CA2361636A1
CA2361636A1 CA002361636A CA2361636A CA2361636A1 CA 2361636 A1 CA2361636 A1 CA 2361636A1 CA 002361636 A CA002361636 A CA 002361636A CA 2361636 A CA2361636 A CA 2361636A CA 2361636 A1 CA2361636 A1 CA 2361636A1
Authority
CA
Canada
Prior art keywords
anaemia
general formula
compounds
treatment
indicated above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361636A
Other languages
English (en)
Inventor
Jurgen Stoltefuss
Gabriele Braunlich
Berthold Hinzen
Thomas Kramer
Josef Pernerstorfer
Thomas Studemann
Ulrich Nielsch
Martin Bechem
Emanuel Lohrmann
Christoph Gerdes
Michael Sperzel
Klemens Lustig
Lorenz Mayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361636A1 publication Critical patent/CA2361636A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des amides d'acides pyrazol-carboxyliques, de formules générales (I) et (Ia), dont certains sont nouveaux et d'autres connus, ainsi que la fabrication desdits amides soit par la chimie en phase solide, soit par l'intermédiaire des nouveaux acides pyrazol-carboxyliques. Ces amides peuvent être utilisés comme médicaments, notamment pour le traitement de l'anémie.
CA002361636A 1999-02-04 2000-01-24 Utilisation d'amides d'acides pyrazol-carboxyliques Abandoned CA2361636A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904397.3 1999-02-04
DE19904397A DE19904397A1 (de) 1999-02-04 1999-02-04 Verwendung von Pyrazol-Carbonsäureamiden
PCT/EP2000/000519 WO2000045894A2 (fr) 1999-02-04 2000-01-24 Utilisation d'amides d'acides pyrazol-carboxyliques

Publications (1)

Publication Number Publication Date
CA2361636A1 true CA2361636A1 (fr) 2000-08-10

Family

ID=7896339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361636A Abandoned CA2361636A1 (fr) 1999-02-04 2000-01-24 Utilisation d'amides d'acides pyrazol-carboxyliques

Country Status (8)

Country Link
EP (1) EP1148879A2 (fr)
JP (1) JP2002536348A (fr)
AR (1) AR022470A1 (fr)
AU (1) AU3150300A (fr)
CA (1) CA2361636A1 (fr)
DE (1) DE19904397A1 (fr)
GT (1) GT200000009A (fr)
WO (1) WO2000045894A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273782B2 (en) 2007-02-07 2012-09-25 Glaxosmithkline Llc Inhibitors of Akt activity
US8609711B2 (en) 2009-01-30 2013-12-17 Glaxosmithkline Llc Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride
US8710038B2 (en) 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
EP4173485A1 (fr) * 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés inhibant l'agrégation de protéine pour la lutte contre les maladies des plantes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
AU7564296A (en) * 1995-11-17 1997-06-11 Ciba-Geigy Ag Solid phase synthesis of heterocyclic compounds and combinatorial compound library
DE19904406A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE19904396A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710038B2 (en) 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use
US8273782B2 (en) 2007-02-07 2012-09-25 Glaxosmithkline Llc Inhibitors of Akt activity
US8410158B2 (en) 2007-02-07 2013-04-02 Glaxosmithkline Llc Inhibitors of Akt activity
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity
US8609711B2 (en) 2009-01-30 2013-12-17 Glaxosmithkline Llc Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride

Also Published As

Publication number Publication date
AR022470A1 (es) 2002-09-04
AU3150300A (en) 2000-08-25
WO2000045894A2 (fr) 2000-08-10
WO2000045894A3 (fr) 2001-04-19
GT200000009A (es) 2001-07-27
DE19904397A1 (de) 2000-08-10
JP2002536348A (ja) 2002-10-29
EP1148879A2 (fr) 2001-10-31

Similar Documents

Publication Publication Date Title
JP4486817B2 (ja) １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体
CN102918034B (zh) 多取代芳族化合物作为凝血酶的抑制剂
JP2002507611A (ja) イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
JP2000143635A (ja) 血管新生阻害剤
HUP0003217A2 (hu) Szubsztituált 2-(2,6-dioxopiperidin-3-il)-ftálimidek és -1-oxoizoindolinok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000095767A (ja) 性腺刺激ホルモン放出ホルモン拮抗剤
WO2008059867A1 (fr) Nouveau dérivé de 1,2-dihydroquinoline comprenant en tant que substituants un groupe alkyle inférieur-carbonyloxy (à substitution phényle ou substitution hétérocyclique) et un groupe phényle lié par un ester
JP4927303B2 (ja) タンパク質Ｊｕｎキナーゼのインヒビターとしての医薬的活性ベンズスルホンアミド誘導体
CN103796992A (zh) 胍基苯甲酸化合物
FI87205C (fi) Foerfarande foer framstaellning av farmakologiskt anvaendbara foereningar
EP2733144B1 (fr) Nouveau composé ayant une activité d'inhibition de parp
CN103443076A (zh) 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
JP2000063363A (ja) 新規なトリアゾール誘導体
JP4564713B2 (ja) 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
JP2003535084A (ja) ベンズアミド誘導体ならびにそのアポｂ−１００およびｍｔｐ阻害剤としての使用
JP2007297283A (ja) 新規桂皮酸関連化合物
WO2008098096A1 (fr) Composés hétérocycliques anti-cytokine
CA2361636A1 (fr) Utilisation d'amides d'acides pyrazol-carboxyliques
JPH10503779A (ja) フェノキシフェニル酢酸誘導体
ZA200606909B (en) Hydrazide type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases
JP3621416B2 (ja) 新規なベンゾジアゼピン誘導体
CA2361816A1 (fr) Acides pyrazolcarboxyliques substitues utilises pour combattre les anemies
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
HUT64311A (en) Process for production propenoyl-imidazole derivatives and pharmaceutical prepartions having these compounds
JPH0753500A (ja) グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤

Legal Events

Date Code Title Description
FZDE Dead